Shanghai Henlius Biotech, Inc.

Detailed Description

Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases worldwide. The company offers HLX01, a rituximab injection for treating non- hodgkin lymphoma and chronic lymphocytic leukemia; Hanquyou, a trastuzumab injection for breast and metastatic gastric cancer; and Han Dayuan, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, and psopiasis and uveitis. It is developing HLX01 for the treatment of rheumatoid arthritis; HLX04 for colorectal and non-squamous non-small cell lung cancer; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX10 for solid tumors and hepatitis B virus; HLX10+Chemotherapy for metastatic esophageal squamous-cell carcinomas, squamous non-small cell lung cancer, small cell lung cancer, neo-/adjuvant treatment of gastric cancer, and cervical cancer; and HLX10+HLX04 for hepatocellular carcinoma, non-squamous, non-small cell lung cancer, and metastatic colorectal cancer. The company is also developing HLX10+HLX07 for squamous cell carcinoma of the head and neck; HLX07, HLX06, HLX56, and HLX20 for solid tumors; HLX05, a cetuximab injection for squamous cell carcinoma of the head and neck and metastatic colorectal cancer; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and metastatic colorectal cancer; HLX22 for breast and metastatic gastric cancer; HLX55 for metastatic or recurrent solid tumors; HLX11 for breast cancer; HLX14 for osteoporosis; HLX13 for unresectable or metastatic melanoma, adjuvant treatment of melanoma, advanced renal cell carcinoma, and metastatic colorectal cancer; HLX15 for multiple myeloma; HLX26 for solid tumor and lymphoma; and HLX70 and HLX71 for COVID-19. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.